ARVO Meeting Coverage Day 1: LIGHTSITE III and DERBY/OAKS at 18 Months
Could photobiomodulation soon be a therapeutic option for patients with dry AMD? Researchers in the LIGHTSITE III study are working toward finding out. We spoke with Marion Munk, MD, PhD, about the details from a study that evaluated the Valeda Light Delivery System (LumiThera) in patients with dry AMD. Were patients able to safely realize any improvement to visual function?\xa0\n\nAnd we checked in with Roger Goldberg, MD, MBA, who detailed the 18-month findings of the DERBY and OAKS studies, a pair of phase 3 clinical trials evaluating the safety and efficacy of pegcetacoplan (APL-2, Apellis Pharmaceuticals) in patients with geographic atrophy. The studies\u2019 primary endpoint was at 1 year. What did they find after an additional 6 months? Stick here to find out.